顺铂联合恩度胸腔灌注治疗肺癌恶性胸腔积液的临床效果和不良反应观察  

Clinical efficacy and adverse reactions of cisplatin combined with endostar thoracic perfusion in the treatment of malignant pleural effusion of lung cancer

作　　者：邹俊韬[1] 胡珍珍[1] 陈颖兰[1] 

机构地区：[1]江西省肿瘤医院胸部肿瘤内科,南昌330029

出　　处：《中国当代医药》2016年第24期22-24,共3页China Modern Medicine

摘　　要：目的 探讨顺铂联合恩度胸腔灌注治疗肺癌恶性胸腔积液的临床效果和不良反应。方法 选取我院2014年12月~2015年11月进行治疗的72例肺癌恶性胸腔积液患者作为研究对象,随机分成研究组和对照组,各36例。对照组采用单纯的顺铂胸腔灌注,研究组采取顺铂联合恩度胸腔灌注。治疗2个周期后,比较两组的临床疗效及不良反应发生率,比较两组在治疗第3天及治疗第7天后的胸腔积液、血清血管内皮因子（VEGF）浓度。结果 研究组的总有效率为80.6%,显著高于对照组的58.3%,差异有统计学意义（P〈0.05）。两组的不良反应发生率比较,差异无统计学意义（P〉0.05）。研究组治疗7 d后的胸腔积液和血清VEGF浓度显著低于治疗3 d后和对照组7 d后,差异有统计学意义（P〈0.05）。结论 顺铂联合恩度胸腔灌注治疗肺癌恶性胸腔积液效果显著,不良反应发生率低,能明显抑制VEGF的表达。Objective To explore the clinical effects and adverse reactions of cisplatin combined with endostar thoracic perfusion in the treatment of malignant pleural effusion of lung cancer.Methods 72 patients with malignant pleural ef- fusion of lung cancer in our hospital from December 2014 to November 2015 were selected and randomly divided into the study group and the control group,36 cases in each group.The control group was treated with cisplatin intrapleural infusion alone,the study group was treated with cisplatin combined with endostar thoracic perfusion.Afier 2 cycles of treatment,the clinical effects and adverse reaction incidence rate of the two groups was compared,and the concentration of the pleural effusion,serum VEGF after treatment for 3 days and 7 days in the two groups was compared.Results The total effective rate in the study group was 80.6%,which was higher than 58.3% in the control group,with significant dif- ference （P〈0.05）.The incidence rate of adverse reactions of the two groups was compared,and the difference was not statistically significant （P〉O.05）.The concentration of the pleural effusion,serum VEGF in the study group after treat- ment for 7 days was lower than that after treatment for 3 days and in the control group after treatment for 7 days,with significant difference （P〈0.05）.Conclusion The treatment effects of cisplatin combined with endostar thoracic perfusion in the treatment of malignant pleural effusion of lung cancer is significant,the incidence rate of adverse reaction is lower, and which can control the expression function of VEGF.

关 键 词：顺铂 恩度 胸腔灌注 肺癌恶性胸腔积液 

分 类 号：R734.2[医药卫生—肿瘤]